Top Markets
Coin of the day
Tianjin Ringpu Bio-Technology Co.,Ltd. Tianjin Ringpu Bio-Technology Co.,Ltd.

Tianjin Ringpu Bio-Technology Co.,Ltd.

300119
Rang in Aktien #8815
Established in 1998 and based in Tianjin, China, Tianjin Ringpu Bio-Technology... Established in 1998 and based in Tianjin, China, Tianjin Ringpu Bio-Technology Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of a broad spectrum of animal health solutions. Their product portfolio includes veterinary biologicals, pharmaceutical formulations, functional feed additives, and active pharmaceutical ingredients (APIs) for the Chinese market. The company provides a wide array of vaccines and medications for livestock, particularly poultry and swine. They also offer a comprehensive line of pet care products, such as inactivated rabies vaccines, recombinant canine-alpha interferon, inhalation anesthetics like isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate injections for bacterial infections, and cardiac treatments including napril chewable tablets. For waterfowl, their specialized offerings include live and inactivated duck tempusu vaccines, purified egg yolk antibodies for gosling plague and duck viral hepatitis, duck infectious serositis inactivated vaccines, as well as injectable and soluble powder treatments like florfenicol and kanamycin. Furthermore, Ringpu develops antifungal products featuring natural plant extracts, immune polysaccharides, probiotics (such as Clostridium butyricum and Lactobacillus plantarum), antibacterial peptides, enzyme preparations, and acidulants. Their disinfection and cleaning range comprises potassium hydrogen persulfate composite powder, various quaternary ammonium compounds (e.g., benzyl trimethyl ammonium chloride, deca methyl ammonium bromide), sodium dichloroisocyanurate, and iodine glycerin solutions. The company's API production includes crucial ingredients like tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, and gamimycin.
Aktienkurs
$2.51
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$1.17B
Veränderung (1 Tag)
0.58%
Veränderung (1 Jahr)
-20.26%
Land
CN
Handel Tianjin Ringpu Bio-Technology Co.,Ltd. (300119)

Kategorie

P/B-Verhältnis für Tianjin Ringpu Bio-Technology Co.,Ltd. (300119)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Tianjin Ringpu Bio-Technology Co.,Ltd. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Tianjin Ringpu Bio-Technology Co.,Ltd. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber